ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Meeting with the Department of Health and Human services on proposal to restrict the use of rebates under Medicare and Medicaid
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY JO CARDEN | Vice President, Government & Pharmacy Affairs |
| CHRISTOPHER J. TOPOLESKI New | — |
Pharmacy PHA
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY JO CARDEN New | Vice President, Government & Pharmacy Affairs |
| CHRISTOPHER J. TOPOLESKI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.